That Prestwick Pharmaceutical's Xenazine's significant efficacy in treating the involuntary movements (chorea) of Huntington's Disease did not translate to a benefit over placebo for non-motor endpoints may be the fault of an inadequate scale to measure functionality, an FDA panel said
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.
